Lawsuits Filed Against BLCT, CRMD and SLQT - Jakubowitz Law Pursues Shareholders Claims

NEW YORK, NY / ACCESSWIRE / September 2, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Bluecity Holdings Limited (NASDAQ:BLCT)

CONTACT JAKUBOWITZ ABOUT BLCT:
https://claimyourloss.com/securities/bluecity-holdings-limited-loss-submission-form/?id=19293&from=1

This lawsuit is on behalf of all persons and entities, other than Defendants, who purchased or otherwise acquired BlueCity American Depositary Shares pursuant and/or traceable to the Offering Documents issued in connection with the Company's initial public offering conducted on or about July 8, 2020.

Lead Plaintiff Deadline: September 17, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Defendants had overstated BlueCity's business and financial prospects; (2) the Company was ill-equipped to absorb the costs of becoming a publicly traded company, including IPO- and growth-related costs; (3) as a result of all the foregoing, Defendants had misrepresented the Company's capability for sustainable growth; and (4) as a result, the Offering Documents were materially false or misleading and/or failed to state information required to be stated therein.

CorMedix Inc. (NASDAQ:CRMD)

CONTACT JAKUBOWITZ ABOUT CRMD:
https://claimyourloss.com/securities/cormedix-inc-loss-submission-form/?id=19293&from=1

Class Period: July 8, 2020 - May 13, 2021

Lead Plaintiff Deadline: September 20, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) deficiencies existed with respect to an investigational drug product, DefenCath's, manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the Food and Drug Administration was unlikely to approve the DefenCath new drug application for catheter-related bloodstream infections in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Selectquote, Inc. (NYSE:SLQT)

CONTACT JAKUBOWITZ ABOUT SLQT:
https://claimyourloss.com/securities/selectquote-inc-loss-submission-form/?id=19293&from=1

Class Period: February 8, 2021 - May 11, 2021

Lead Plaintiff Deadline: October 15, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) SelectQuote's 2019 cohort was underperforming; (2) as a result, the Company's financial results would be adversely impacted; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law
 



View source version on accesswire.com:
https://www.accesswire.com/662556/Lawsuits-Filed-Against-BLCT-CRMD-and-SLQT--Jakubowitz-Law-Pursues-Shareholders-Claims

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.